24127-36-4Relevant articles and documents
Iridium/f-Amphol-catalyzed Efficient Asymmetric Hydrogenation of Benzo-fused Cyclic Ketones
Yin, Congcong,Dong, Xiu-Qin,Zhang, Xumu
, p. 4319 - 4324 (2018/10/15)
Iridium/f-Amphol-catalyzed asymmetric hydrogenation of various benzo-fused five to seven-membered cyclic ketones was successfully developed, affording a series of chiral benzo-fused cyclic alcohols with excellent results (75%–99% yields, 93%–>99% ee, and TON up to 297 000). The enantioenriched products can be employed as key intermediates or motifs for the synthesis of some important biologically active compounds, such as rasagiline mesylate TVP-1012 used for the treatment of Parkinson's disease, the enantiomer of anticonvulsant drug eslicarbazepine acetate (BIA 2-093). (Figure presented.).
Targeting the hinge glycine flip and the activation loop: Novel approach to potent p38α inhibitors
Martz, Kathrin E.,Dorn, Angelika,Baur, Benjamin,Schattel, Verena,Goettert, Márcia I.,Mayer-Wrangowski, Svenja C.,Rauh, Daniel,Laufer, Stefan A.
, p. 7862 - 7874 (2012/10/29)
The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines. Small molecule p38 inhibitors suppress the production of these cytokines. Therefore p38 is a promising drug target for novel anti-inflammatory drugs. In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38α MAP kinase inhibitors. Previously reported dibenzepinones and dibenzoxepines were chemically modified by introduction of functional groups or removal of a phenyl ring. This should result in targeting of the hydrophobic region I, the "deep pocket", and the hinge glycine flip of the kinase. Potent inhibitors with IC50 values in the single digit nanomolar range (up to 3 nM) were identified. Instead of targeting the "deep pocket" in the DFG-out conformation, interactions with the DFG-motif in the in-conformation could be observed by protein X-ray crystallography.
HMG-CoA reductase inhibitors
-
Page/Page column 93, (2010/11/28)
Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and trea
Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
-
Page/Page column 16-17, (2010/02/11)
The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula: in which R1 represents a C3-C15 carboxyl radical or an NR2R3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB1 receptors.
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′, 4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7] cyclohepta[1,2-c]pyrazole-3-carboxamide
Murineddu, Gabriele,Ruiu, Stefania,Loriga, Giovanni,Manca, Ilaria,Lazzari, Paolo,Reali, Roberta,Pani, Luca,Toma, Lucio,Pinna, Gérard A.
, p. 7351 - 7362 (2007/10/03)
A series of analogues of 8-chloro-1-(2′,4′-dichlorophenyl)-AT- piperidin-1-yl-1,4,5,6-tetrahydrobenzo-[6,7]cyclohepta[1,2-c] pyrazole-3-carboxamide 4a (NESS 0327) (Ruiu, S.; Pinna, G. A.; Marchese, G.; Mussinu, J. M.; Saba, P.; Tambaro, S.; Casti, P.; Var
Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor
Ruiu, Stefania,Pinna, Gerard A.,Marchese, Giorgio,Mussinu, Jean-Mario,Saba, Pierluigi,Tambaro, Simone,Casti, Paola,Vargiu, Romina,Pani, Luca
, p. 363 - 370 (2007/10/03)
The compound N-piperidinyl-[8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo [6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide] (NESS 0327) was synthesized and evaluated for binding affinity toward cannabinoid CB1 and CB2 receptor.
